Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Sees Significant Growth in Short Interest

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) was the target of a significant growth in short interest during the month of October. As of October 30th, there was short interest totaling 2,838 shares, a growth of 1,319.0% from the October 15th total of 200 shares. Based on an average daily trading volume, of 2,344 shares, the short-interest ratio is presently 1.2 days. Approximately 0.0% of the shares of the company are sold short.

Santen Pharmaceutical Price Performance

Shares of SNPHY traded up $0.06 during mid-day trading on Wednesday, hitting $12.73. 1,894 shares of the company’s stock were exchanged, compared to its average volume of 2,256. Santen Pharmaceutical has a fifty-two week low of $9.50 and a fifty-two week high of $13.93. The business’s 50 day moving average is $11.16 and its two-hundred day moving average is $11.53.

About Santen Pharmaceutical

Santen Pharmaceutical is a Japan-based pharmaceutical company focused on eye care. Founded in 1890, it researches, develops, manufactures and markets treatments for ophthalmic conditions. Its products include prescription medicines for conditions such as glaucoma, dry eye and retinal diseases, as well as over-the-counter eye drops and other eye-care products. The company also offers products for eye surgery and related medical needs. Headquartered in Osaka, Santen serves patients and healthcare professionals in Japan and international markets, including other parts of Asia, Europe and the Middle East and Africa.